Biopharma dive · 7h ago
FDA clears first generic radioligand drug; Sionna turns to layoffs
A Lutathera copycat has become the first “radioligand equivalent” cleared by regulators. Elsewhere, Novo dropped the “Nordisk” from its name and a novel RNAi drug showed early promise.
Rhyter Times aggregates short excerpts. The full story is reported by Biopharma dive.
Read the full story at Biopharma dive →